40.62USD-5.27%Mkt Cap: 1.83B USDP/E: —Last update: 2026-06-01
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-dire…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.83B USD
Enterprise Value1.73B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.27M USD
Revenue/Share—
Last Price40.62 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.28
PEG—
EV/EBITDA-17.55
EV/Revenue—
P/S—
P/B6.70
EPS (TTM)-1.86
EPS (Forward)-2.80
52W Range
13.2678% of range48.45
52W High48.45 USD
52W Low13.26 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-24.53%
ROA-23.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-66.30M USD
CapEx (TTM)377.00K USD
FCF Margin—
FCF Yield-2.50%
Net Debt-207.77M USD
Net Debt/EBITDA2.11
Balance Sheet
Debt/Equity0.03
Current Ratio22.60
Quick Ratio22.11
Book Value/Sh6.394 USD
Cash/Share4.787 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)51.60 USD
Target Range23.00 USD – 63.00 USD
# Analysts10
Ownership
Shares Out.45.15M
Float16.80M
Insiders6.85%
Institutions100.21%
Short Interest
Short Ratio10.3d
Short % Float17.05%
Short % Out.10.50%
Shares Short4.74M
Short (prev mo.)3.80M
Technical
SMA 5040.29 (+0.8%)
SMA 20036.31 (+11.9%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)359.78K
Avg Vol (10d)317.56K
Technical Indicators
RSI (14)54.4
MACD0.5556
MACD Signal0.4292
MACD Hist.+0.1264
BB Upper45.85 USD
BB Middle41.78 USD
BB Lower37.72 USD
BB Width19.47%
ATR (14)2.731 USD
Vol Ratio (20d)0.62x